Table 1.
Baseline characteristics of the included trials.
| Study | Case (n) | Sex (M/F) |
Age (y) | Intervention | Baseline FBG (mmol/L) | Dose (g/d) | Outcome measured time (weeks) | |
|---|---|---|---|---|---|---|---|---|
| G | C | |||||||
| Ashraf 2005 [11] | 35/35 | 15/20 | 17/18 | 60 ± 5.04/58 ± 5.80 | Garlic/placebo | NR | 0.6 | Ranged at 6, 12 |
| Sobenin 2008 [12] | 10/10 | 8/12 | 48.2 ± 2.6 | Garlic/placebo | 7.7 ± 0.6/7.6 ± 0.6 | 0.6 | Ranged at 1, 2, 3, 4 | |
| 20/20 | 18/22 | Garlic+SF/placebo+SF | 9.7 ± 0.4/10.1 ± 0.8 | |||||
| Sukandar 2010 [13] | 32/32 | 5/27 | 54.5 ± 8.4 | Garlic/control | 9.7 ± 2.8 | 1.2, 1.6, 2.4 | Ranged at 2, 4, 6, 8, 10, 12 | |
| Ashraf 2011 [14] | 30/30 | 17/13 | 16/14 | 40 ± 5.04/35 ± 4.58 | Garlic+MT/placebo+MT | 7.1 ± 0.3/6.2 ± 0.5 | 0.9 | Ranged at 12, 24 |
| Ashraf M 2011 [15] | 150/30 | 90/60 | 15/15 | 40 ± 5.04/45 ± 4.58 | Garlic/placebo | 7.1 ± 0.3/7.1 ± 0.2 | 0.3, 0.6, 0.9, 1.2, 1.5 | Ranged at 12, 24 |
| Song 2006 [16] | 46/50 | 55/41 | 52 ± 9 | Garlic+insulin/insulin | 10.7 ± 2.7/12.2 ± 3.1 | 0.06 | Post-treatment 2 | |
| Chhatwal 2012 [17,18] | 30/30 | NR | 53.8 ± 12.2/52.8 ± 11.0 | Garlic+MT/MT | 8.4 ± 0.8/9.0 ± 0.9 | 0.5 | Ranged at 2, 4, 6, 8, 12 | |
| Manafikhi 2015 [19] | 51/45 | NR | 30–70 | Garlic+MT+GB/MT+GB | 12.0 ± 0.6/9.6 ± 0.5 | 0.05 | Post-treatment 12 | |
| Atkin 2016 [20] | 26/26 | 19/7 | 18–70 | Garlic/placebo | - | 1.2 | Post-treatment 4 | |
G, garlic group; C, control group; NR, not reported; FBG, fasting blood glucose; SF, sulfonylurea; MT, metformin; GB, glyburide.
Data were listed as mean±deviation or range.